Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion PharmaDHA:ORIONPHARM -0.40%75 Shiller PE Ratio is 8.45 as of Sep. 10, 2026, which is 13% below its 10-year median of 9.74. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 75/100 and a GF Value™ of BDT19.52 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 203 Utilities - Independent Power Producers companies, Orion Pharma ranks better than 73.4% on this metric.
As of today (2026-09-10), Orion Pharma's current share price is BDT25.00. Orion Pharma's E10 for the quarter that ended in Mar. 2026 was BDT2.96. Orion Pharma's Shiller PE Ratio for today is 8.45.
The historical rank and industry rank for Orion Pharma's Shiller PE Ratio or its related term are showing as below:
DHA:ORIONPHARM'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.02 Med: 9.74 Max: 20.07
Current: 8.93
During the past years, Orion Pharma's highest Shiller PE Ratio was 20.07. The lowest was 7.02. And the median was 9.74.
DHA:ORIONPHARM's Shiller PE Ratio is ranked better than 73.4% of 203
companies
in the Utilities - Independent Power Producers industry
Industry Median: 14.72
vs DHA:ORIONPHARM: 8.93
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Orion Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was BDT-0.650. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is BDT2.96 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Orion Pharma (DHA:ORIONPHARM) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Orion Pharma Shiller PE Ratio Related Terms
Orion Pharma Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Shiller PE Ratio Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Shiller PE Ratio vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Orion Pharma's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma's E10 for the quarter that ended in Mar. 2026 is calculated as:
For example, Orion Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Orion Pharma (DHA:ORIONPHARM) has a Shiller PE Ratio of 8.45 as of Sep. 10, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Orion Pharma and its competitors. This is 13% below median its historical median of 9.74. Over the past decade, Orion Pharma's Shiller PE Ratio has ranged from 7.02 to 20.07. According to the industry distribution chart, Orion Pharma ranks #54 out of 203 companies in the Utilities - Independent Power Producers industry, placing it in the top 26.6%.
Is Orion Pharma's Shiller PE Ratio too high?
Orion Pharma's current Shiller PE Ratio of 8.45 is 13% below median its 10-year median of 9.74. Over the past 10 years, this metric has ranged from a low of 7.02 to a high of 20.07. The Utilities - Independent Power Producers industry median Shiller PE Ratio is 14.72. Orion Pharma's value of 8.45 is 42.6% below this industry median. Based on the distribution chart, Orion Pharma ranks #54 out of 203 companies in the Utilities - Independent Power Producers industry, which is above the industry midpoint. Overall, Orion Pharma has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Shiller PE Ratio compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #54 out of 203 companies for Shiller PE Ratio. This puts Orion Pharma in the upper half of its industry. The industry median Shiller PE Ratio is 14.72. Orion Pharma's value of 8.45 is 42.6% below this benchmark. Historically, Orion Pharma's own Shiller PE Ratio has ranged from 7.02 to 20.07 over the past decade. While the company's 10-year median is 9.74 vs. the industry median of 14.72, Orion Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for an Utilities - Independent Power Producers company?
The median Shiller PE Ratio among Utilities - Independent Power Producers companies is 14.72, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Shiller PE Ratio of 8.45 is 42.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Shiller PE Ratio is 14.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Shiller PE Ratio is 8.45, which is 13% below median its own 10-year median of 9.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT19.52, compared to a current price of BDT25.00 — trading 28.1% above its estimated fair value. The current Shiller PE Ratio is 8.45, which is 13% below median its 10-year median of 9.74 and 42.6% below the Utilities - Independent Power Producers industry median of 14.72. Orion Pharma's overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Shiller PE Ratio is 8.45 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT25.00 is trading 28.1% above its estimated GF Value™ of BDT19.52.
GuruFocus considers Orion Pharma to be Modestly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Shiller PE Ratio: 8.45 (13% below median its 10-year median of 9.74)
GF Value™: BDT19.52 vs. price of BDT25.00 (28.1% above fair value)
Industry Position: 42.6% below the Utilities - Independent Power Producers median (#54 of 203)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
75GF Score
Get the complete analysis for DHA:ORIONPHARM
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
